Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments

Figure 5

Knockdown of Nrf2-sensitized K562/G01 cells to imatinib treatments.